PM
TERN

Prosight Management’s Terns Pharmaceuticals TERN Stock Holding History

Prosight Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7M Buy
202,300
+107,300
+113% +$4.41M 1.75% 19
2025
Q4 		$3.84M Buy
+95,000
New +$2.2M 0.79% 28

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Prosight Management's TERN Position: Q1 2026 in Review

Prosight Management increased its Terns Pharmaceuticals (TERN) stake by 113% in Q1 2026, buying an estimated $4.41M and bringing the position to 202,300 shares worth $10.7M. The position accounts for 1.75% of the portfolio, ranked #19.

Prosight Management first reported a position in TERN in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Prosight Management held 202,300 shares of Terns Pharmaceuticals worth $10.7M as of Q1 2026.
  • Prosight Management bought 107,300 Terns Pharmaceuticals shares in Q1 2026, an estimated $4.41M.
  • Terns Pharmaceuticals made up 1.75% of Prosight Management's portfolio in Q1 2026, its #19 holding.
  • Prosight Management first reported a position in Terns Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.